Literature DB >> 18469710

Ossifying fibromyxoid tumor of soft parts--a clinicopathologic and immunohistochemical study of 104 cases with long-term follow-up and a critical review of the literature.

Markku Miettinen1, Val Finnell, John F Fetsch.   

Abstract

Ossifying fibromyxoid tumor (OFT) is a unique soft tissue tumor of uncertain histogenesis. The majority of reported cases (approximately 220) have pursued a benign clinical course. However, recent literature has emphasized the existence of morphologically atypical and clinically malignant examples of this tumor and proposed guidelines for assessment of biologic potential. In the present study, we evaluated 104 cases of OFT from the Armed Forces Institute of Pathology, accessioned between the years 1970 and 2007. Herein, OFT was strictly defined as a tumor with lobular architecture, predominantly epithelioid cell morphology, a low level of atypia, corded and trabecular growth patterns, moderate amounts of myxocollagenous matrix, and often, focal peripheral metaplastic bone formation. Tumors that lacked conventional morphology were excluded. The exclusion group included cutaneous mixed tumors, low-grade fibromyxoid sarcomas, and extraskeletal osteosarcomas. The OFTs occurred in 64 men and 40 women with a median age of 50 years (range, 21 to 81 y). The tumor size ranged from 0.7 to 17 cm (median, 3 cm). The mitotic rate varied from 0 to 41 mitotic figures per 50 HPFs (median, 2/50 HPFs). Tumor cell nuclei typically contained small, distinct nucleoli, and necrosis was infrequent (11/104). The great majority of tumors (67/71, 94%) were positive for S100 protein, whereas only occasional examples had (focal) positivity for desmin, glial fibrillary acidic protein, and an AE1/AE3 keratin cocktail. Local recurrences were documented in 9 of 41(22%) living patients, usually 10 or more years after primary surgery, but there were no metastases. A mitotic rate of >2 mitotic figures/50 HPFs was a risk factor for local recurrence, but necrosis, tumor size, the presence of satellite nodules, and positive margins were not. When OFT is strictly defined by the criteria noted above, there is potential for local recurrence, but there seems to be little or no risk for metastasis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18469710     DOI: 10.1097/PAS.0b013e318160736a

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  24 in total

Review 1.  Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems.

Authors:  Fausto J Rodriguez; Andrew L Folpe; Caterina Giannini; Arie Perry
Journal:  Acta Neuropathol       Date:  2012-02-12       Impact factor: 17.088

2.  Novel recurrent PHF1-TFE3 fusions in ossifying fibromyxoid tumors.

Authors:  Albert J H Suurmeijer; Wangzhao Song; Yun-Shao Sung; Lei Zhang; David Swanson; Christopher D M Fletcher; Brendan C Dickson; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2019-04-17       Impact factor: 5.006

3.  Atypical ossifying fibromyxoid tumor unusually located in the mediastinum: report of a case showing mosaic loss of INI-1 expression.

Authors:  Shogo Tajima; Kenji Koda
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

4.  Expanding the molecular signature of ossifying fibromyxoid tumors with two novel gene fusions: CREBBP-BCORL1 and KDM2A-WWTR1.

Authors:  Yu-Chien Kao; Yun-Shao Sung; Lei Zhang; Chun-Liang Chen; Shih-Chiang Huang; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2016-08-26       Impact factor: 5.006

5.  Ossifying fibromyxoid tumor of soft parts: a clinicopathologic, proteomic, and genomic study.

Authors:  Rondell P D Graham; Sarah Dry; Xinmin Li; Scott Binder; Armita Bahrami; Susana C Raimondi; Ahmet Dogan; Subhankar Chakraborty; Joshua J Souchek; Andrew L Folpe
Journal:  Am J Surg Pathol       Date:  2011-11       Impact factor: 6.394

6.  Novel ZC3H7B-BCOR, MEAF6-PHF1, and EPC1-PHF1 fusions in ossifying fibromyxoid tumors--molecular characterization shows genetic overlap with endometrial stromal sarcoma.

Authors:  Cristina R Antonescu; Yun-Shao Sung; Chun-Liang Chen; Lei Zhang; Hsiao-Wei Chen; Samuel Singer; Narasimhan P Agaram; Andrea Sboner; Christopher D Fletcher
Journal:  Genes Chromosomes Cancer       Date:  2013-11-28       Impact factor: 5.006

7.  Updates on the cytogenetics and molecular cytogenetics of benign and intermediate soft tissue tumors.

Authors:  Jun Nishio
Journal:  Oncol Lett       Date:  2012-10-30       Impact factor: 2.967

8.  PHF1 fusions cause distinct gene expression and chromatin accessibility profiles in ossifying fibromyxoid tumors and mesenchymal cells.

Authors:  Jakob Hofvander; Vickie Y Jo; Christopher D M Fletcher; Florian Puls; Uta Flucke; Jenny Nilsson; Linda Magnusson; Fredrik Mertens
Journal:  Mod Pathol       Date:  2020-01-13       Impact factor: 7.842

9.  Myoepithelioma within the carpal tunnel: a case report and review of the literature.

Authors:  Jonathan Cm Clark; Stuart J Galloway; Stephen M Schlicht; Ross Pv McKellar; Peter Fm Choong
Journal:  Int Semin Surg Oncol       Date:  2009-09-09

10.  Ossifying fibromyxoid tumor of the oral cavity: rare case report and long-term follow-up.

Authors:  Maria Eduarda Pérez-de-Oliveira; Thayná Melo de Lima Morais; Márcio Ajudarte Lopes; Oslei Paes de Almeida; Willie F P van Heerden; Pablo Agustin Vargas
Journal:  Autops Case Rep       Date:  2020-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.